Compare IVA & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IVA | HBIO |
|---|---|---|
| Founded | 2011 | 1901 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 769.0M | 33.8M |
| IPO Year | 2020 | 2000 |
| Metric | IVA | HBIO |
|---|---|---|
| Price | $4.55 | $0.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $17.14 | $2.50 |
| AVG Volume (30 Days) | 237.5K | ★ 1.1M |
| Earning Date | 09-29-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $19,929,536.00 | ★ $87,371,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.11 | $0.28 |
| 52 Week High | $7.98 | $2.38 |
| Indicator | IVA | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.25 | 61.63 |
| Support Level | $4.05 | $0.71 |
| Resistance Level | $4.61 | $0.81 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 89.23 | 70.05 |
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.